Project Grant R01HL186183
Award Date 6/15/26
Completion Date 3/31/30
Dollars Obligated $753K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Nashville, TN 37203, USA
Similar Awards
- Federal Grant Award Summary Vanderbilt University received a $489,644 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 1, 2025, with completion targeted for July 31, 2027. The project aims to develop novel drug-coated balloon (DCB) therapies using peptide-based delivery mechanisms to improve long-term vessel patency following angioplasty in peripheral arterial disease (PAD) treatment....
- Federal Grant Award Summary Vanderbilt University Medical Center (VUMC) received a $883,216 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), with an award date of May 1, 2026 and completion deadline of February 28, 2030. The grant supports basic and translational research investigating the pathophysiological role of mitochondrial cyclophilin D (CypD) acetylation in vascular dysfunction and hypertension....
- Federal Project Grant Award Summary Vanderbilt University received a $122,734.00 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective July 27, 2025, with a completion date of May 31, 2028. The award funds research investigating the attenuation of sepsis-induced microvascular permeability and inflammation using liraglutide, a glucagon-like peptide-1 receptor (GLP-1R) agonist. The project...
- Federal Grant Award Summary Vanderbilt University Medical Center received a $158,544 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 1, 2025 through July 31, 2030. This award supports research aimed at identifying high-risk TET2 (Ten-Eleven Translocation methylcytosine dioxygenase 2) mutations associated with clonal hematopoiesis of indeterminate potential (CHIP) and its role in...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Vanderbilt University Medical Center a $3.04 million Project Grant on August 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the intersection of immunity and cardiovascular disease through August 2030. The award supports two primary research projects designed to elucidate how immune cell activation contributes to organ damage in hypertension and autoimmune diseases....
- Federal Project Grant Award Summary Vanderbilt University, through its Sponsored Programs Administration division, received a $744,145 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) on September 4, 2025, with completion targeted for May 31, 2029. The grant supports the development of mirror-image natural products as antiarrhythmic therapeutics, specifically focusing on compounds based on ent-verticilide...
- Federal Project Grant Award Summary Vanderbilt University received a $759,030 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025, through May 31, 2029. The grant supports research to decouple mitral valve-left ventricular (LV) fibrotic remodeling in degenerative mitral regurgitation through investigation of serotonin 2B receptor (5-HT2B) signaling. The primary deliverables include:...
- Federal Grant Award Summary Vanderbilt University Medical Center received a $2.59 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded May 15, 2026, with completion targeted for February 29, 2028. The grant funds research investigating the contribution of superoxide influx via leucine-rich repeat containing 8 (LRRC8) anion channels to vascular dysfunction in infectious disease contexts. The...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Vanderbilt University Medical Center a $170,640 Project Grant (CFDA 93.837: Cardiovascular Diseases Research) on September 19, 2025, with completion targeted for August 31, 2030. This K08 Career Development Award supports a five-year research and training initiative led by Dr. Niedermeyer under the mentorship of Dr. Larissa Shimoda and Dr. Mahendra Damarla. The grant funds both scientific investigation into...
- Federal Grant Award Summary Vanderbilt University Medical Center received a $1.73 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded June 1, 2026, with completion targeted for February 29, 2028. The award funds the therapeutic development of ENT-verticilide, a selective ryanodine receptor type 2 (RYR2) inhibitor, as a novel antiarrhythmic drug for treating atrial fibrillation (AF). The project...